Blueprint Medicines (BPMC)

Trade BPMC now with
2/13/2020 8:13:27 AM Blueprint Medicines Q4 Loss Per Share $1.5 Vs Loss $1.83 Last Year
2/6/2020 8:18:33 AM Blueprint Medicines Announces PDUFA Date Extension For NDA Of Avapritinib By Three Months To May 14, 2020
1/22/2020 10:32:53 PM Blueprint Medicines Prices Underwritten Public Offering Of 4.71 Mln Shares $69.00/shr
1/8/2020 8:11:54 AM Blueprint Medicines Announces Top-line Data For Pralsetinib
1/6/2020 8:12:06 AM CStone, Blueprint Initiate Phase 1b/2 Trial Of Fisogatinib In Combination With CS1001 For Patients With HCC
11/5/2019 7:17:22 AM Blueprint Medicines Q3 Net Loss $94.3 Mln Or $1.93/shr Vs. Net Loss $72.7 Mln Or $1.66/shr Last Year
10/28/2019 8:09:40 AM Blueprint : FDA To Split Avapritinib NDA Into Separate Submissions For PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST
8/7/2019 8:17:17 AM Blueprint Medicines Says FDA Accepts NDA For Avapritinib For PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST
8/1/2019 7:08:37 AM Blueprint Medicines Q2 Net Loss $99.7 Mln Vs. Net Loss $27 Mln Last Year
6/15/2019 6:03:48 AM Blueprint Medicines Presents Updated EXPLORER Trial Data For Avapritinib In Patients With Systemic Mastocytosis
6/14/2019 8:48:43 AM Blueprint Medicines Submits New Drug Application To FDA For Avapritinib
5/9/2019 7:14:21 AM Blueprint Medicines Q1 Net Loss Widens To $87.4 Mln Or $1.98/shr From $56.5 Mln Or $1.29/shr Last Year
4/2/2019 4:01:48 PM Blueprint Medicines Announces Closing Of Public Offering
3/27/2019 4:09:41 PM Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock
2/26/2019 7:13:55 AM Blueprint Medicines Q4 Net Loss $80.3 Mln Or $1.83/Shr Vs Loss Of $49.0 Mln Or $1.23/Shr Last Year